Inventiva S.A. (IVA) shareholders
Close on Nov 17, 2026Market cap $622.22MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph Anderson Joint filing with Sofinnova Partners SAS, a French corporation (8.60%), Antoine Papiernik (8.60%) and 4 more | 19,086,050 | 8.60% | 13G (passive) amendment | Dec 31, 2025 |
| BioDiscovery 6 FPCI Joint filing with Andera Partners (6.70%), Stephane Bergez (6.70%) and 1 more | 15,929,476 | 6.70% | 13G (passive) amendment | Sep 30, 2026 |
| Invus Public Equities Advisors, LLC Joint filing with Invus Public Equities, L.P. (10.60%), Invus Global Management, LLC (10.60%) and 2 more | 14,814,813 | 10.60% | 13G (passive) amendment | Jun 30, 2025 |
| Andera Partners Joint filing with BioDiscovery 6 FPCI (7.70%), Stephane Bergez (7.70%) and 1 more | 14,114,476 | 7.70% | 13G (passive) amendment | Dec 31, 2025 |
| Srinivas Akkaraju | 13,540,194 | 7.40% | 13D (active) amendment | Nov 17, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (6.07%), Deep Track Biotechnology Master Fund, Ltd. (6.07%) | 11,668,983 | 6.07% | 13G (passive) | Jan 23, 2026 |
| Dr. Jeffrey R. Jay, M.D. Joint filing with Great Point Partners, LLC (7.42%), Ms. Lillian Nordahl (7.42%) | 10,576,827 | 7.42% | 13G (passive) | May 5, 2025 |
| Finny Kuruvilla, M.D. Ph. D. Joint filing with Eventide Asset Management, LLC (6.70%), Robin C. John (6.70%) | 10,118,517 | 6.70% | 13G (passive) | May 9, 2025 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (6.10%), Lampert Mark N (6.10%) and 1 more | 8,545,499 | 6.10% | 13D (active) amendment | May 7, 2025 |
| Rick Yang Joint filing with New Enterprise Associates 17, L.P. (6.00%), NEA Partners 17, L.P. (6.00%) and 12 more | 8,350,730 | 6.00% | 13D (active) amendment | May 7, 2025 |
| Samsara BioCapital, L.P. Joint filing with Samsara BioCapital GP, LLC (5.90%), Srinivas Akkaraju (5.90%) | 8,161,942 | 5.90% | 13D (active) | May 7, 2025 |
| Cedric Moreau Joint filing with Sofinnova Crossover I SLP (7.20%), Sofinnova Partners SAS, a French corporation (7.20%) and 4 more | 7,792,307 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
| Yiheng Capital Partners, L.P. Joint filing with Yiheng Capital, LLC (5.46%), Yiheng Capital Management, LP (5.46%) and 1 more | 7,597,148 | 5.46% | 13G (passive) amendment | Sep 30, 2025 |
| Siren, L.L.C. Joint filing with Invus Public Equities, L.P. (7.80%), Invus Public Equities Advisors, LLC (7.80%) and 2 more | 7,407,406 | 7.80% | 13G (passive) | Oct 17, 2024 |
| Francois Xavier Mauron Joint filing with Andera Partners (6.50%), BioDiscovery 6 FPCI (6.50%) and 1 more | 6,148,147 | 6.50% | 13G (passive) | Oct 17, 2024 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.80%), Perceptive Life Sciences Master Fund, Ltd. (5.80%) | 5,555,555 | 5.80% | 13G (passive) | Dec 13, 2024 |
| Yuanshan Guo Joint filing with Yiheng Capital Partners, L.P. (8.31%), Yiheng Capital, LLC (8.31%) and 1 more | 4,331,196 | 8.31% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IVA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Caligan Partners LP | 8,163,191 | – | $30.86M | +3,188,285 | 1.45% |
| Samsara BioCapital, LLC | 6,314,805 | – | $23.87M | +1,120,000 | 1.96% |
| Nantahala Capital Management, LLC | 5,372,786 | – | $20.31M | New | 0.34% |
| Paradigm Biocapital Advisors LP | 4,000,000 | – | $15.12M | – | 0.28% |
| Andera Partners | 3,633,181 | – | $13.73M | +1,815,000 | 6.65% |
| ADAR1 Capital Management, LLC | 3,606,656 | – | $13.63M | +1,432,258 | 0.62% |
| Millennium Management LLC | 3,512,174 | – | $13.28M | +524,561 | 0.00% |
| Trails Edge Capital Partners, LP | 2,657,997 | – | $10.05M | – | 1.60% |
| Franklin Resources Inc | 2,642,611 | – | $9.99M | +181,046 | 0.00% |
| Squadron Capital Management LLC | 2,435,000 | – | $9.20M | +1,900,000 | 2.86% |
| Woodline Partners LP | 2,323,149 | – | $8.78M | New | 0.03% |
| abrdn plc | 2,307,773 | – | $8.72M | New | 0.01% |
| UBS Group AG | 2,305,192 | – | $8.71M | −13,501 | 0.00% |
| Boothbay Fund Management, LLC | 2,003,782 | – | $7.57M | +533,375 | 0.10% |
| Patient Square Capital LP | 1,967,171 | – | $7.44M | New | 1.15% |
| NEXTBio Capital Management LP | 1,787,984 | – | $6.76M | +454,500 | 3.11% |
| Citadel Advisors LLC | 1,784,566 | – | $6.75M | +1,719,616 | 0.00% |
| Ameriprise Financial Inc | 1,697,148 | – | $6.42M | +852,933 | 0.00% |
| Point72 Asset Management, L.P. | 1,683,012 | – | $6.36M | +726,791 | 0.01% |
| Integral Health Asset Management, LLC | 1,520,000 | – | $5.75M | +1,120,000 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | 87M | 31 / 36 | 7 / 7 | 41M | 4M |
| Q1 2026 | 65 | 52M | 22 / 21 | 10 / 10 | 10M | 5M |
| Q4 2025 | 53 | 47M | 38 / 6 | 1 / 0 | 44M | 2M |
| Q3 2025 | 15 | 5M | 5 / 3 | 1 / 2 | 0M | 0M |
| Q2 2025 | 12 | 5M | 4 / 2 | 2 / 0 | 0M | 0M |
| Q1 2025 | 8 | 5M | 1 / 1 | 2 / 0 | 0M | 1M |
| Q4 2024 | 7 | 5M | 2 / 2 | 0 / 2 | 1M | 0M |
| Q3 2024 | 7 | 5M | 1 / 1 | 1 / 1 | 0M | 0M |
| Q2 2024 | 7 | 5M | 0 / 2 | 1 / 1 | 0M | 0M |
| Q1 2024 | 8 | 5M | 2 / 2 | 1 / 3 | 0M | 0M |
| Q4 2023 | 9 | 5M | 1 / 2 | 2 / 0 | 0M | 0M |
| Q3 2023 | 8 | 5M | 2 / 1 | 1 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
9 funds held IVA in Q2 2026, 14% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IVA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | 1,014,919 | – | $4.55M | 0.39% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 685,400 | – | $3.07M | 0.14% | Jul 31, 2026 |
| Simplify Propel Opportunities ETF | 313,483 | – | $1.18M | 1.53% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 154,400 | – | $691.71K | 0.05% | Jul 31, 2026 |
| Artisan International Small-Mid Fund | 144,292 | – | $545.42K | 0.02% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 136,161 | – | $610.00K | 0.04% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 42,752 | – | $161.60K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 34,355 | – | $169.37K | 0.00% | May 31, 2026 |
| Harbor Health Care ETF | 33,996 | – | $152.30K | 0.37% | Jul 31, 2026 |
| ActivePassive International Equity ETF | 8,145 | – | $40.15K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Stock K6 Fund | 2,400 | – | $10.75K | 0.05% | Jul 31, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inventiva's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,900 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?